

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Sohn Tom</u>			2. Issuer Name and Ticker or Trading Symbol <u>Acutus Medical, Inc. [AFIB]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>SVP, Gen. Counsel & Secretary</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>07/25/2022</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O ACUTUS MEDICAL, INC. 2210 FARADAY AVE., SUITE 100			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>CARLSBAD CA 92008</u>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								64,046	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Options (Right to Buy)	\$14.81	07/25/2022		D ⁽¹⁾			41,134	(1)	03/04/2030	Common Stock	41,134	(1)	94,822	D	
Employee Stock Options (Right to Buy)	\$1.34	07/25/2022		A ⁽¹⁾		41,134		(1)	03/04/2030	Common Stock	41,134	(1)	135,956	D	
Employee Stock Options (Right to Buy)	\$18	07/25/2022		D ⁽²⁾			28,022	(2)	08/05/2030	Common Stock	28,022	(2)	107,934	D	
Employee Stock Options (Right to Buy)	\$1.34	07/25/2022		A ⁽²⁾		28,022		(2)	08/05/2030	Common Stock	28,022	(2)	135,956	D	
Employee Stock Options (Right to Buy)	\$13.66	07/25/2022		D ⁽³⁾			34,800	(3)	04/01/2031	Common Stock	34,800	(3)	101,156	D	
Employee Stock Options (Right to Buy)	\$1.34	07/25/2022		A ⁽³⁾		34,800		(3)	04/01/2031	Common Stock	34,800	(3)	135,956	D	
Employee Stock Options (Right to Buy)	\$2.41	07/25/2022		D ⁽⁴⁾			32,000	(4)	02/01/2032	Common Stock	32,000	(4)	103,956	D	
Employee Stock Options (Right to Buy)	\$1.34	07/25/2022		A ⁽⁴⁾		32,000		(4)	02/01/2032	Common Stock	32,000	(4)	135,956	D	

Explanation of Responses:

- The two reported transactions involved an amendment of an outstanding option reducing the exercise price of the option. The option was originally granted on March 4, 2020, with 1/4 vesting on the first anniversary of the vesting commencement date, and the remainder vesting in 36 equal monthly installments.
- The two reported transactions involved an amendment of an outstanding option reducing the exercise price of the option. The option was originally granted on August 5, 2020, with 1/4 vesting on the first anniversary of the vesting commencement date, and the remainder vesting in 36 equal monthly installments.
- The two reported transactions involved an amendment of an outstanding option reducing the exercise price of the option. The option was originally granted on April 1, 2021, with 1/4 vesting on the first anniversary of the vesting commencement date, and the remainder vesting in 36 equal monthly installments.
- The two reported transactions involved an amendment of an outstanding option reducing the exercise price of the option. The option was originally granted on February 1, 2022, with 1/2 vesting on the first anniversary of the vesting commencement date, and the remainder vesting in 12 equal monthly installments.

/s/ Tom Sohn

08/01/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.